<DOC>
	<DOCNO>NCT00672997</DOCNO>
	<brief_summary>The purpose study demonstrate equivalent safety IOP-lowering effectiveness two Travoprost/Timolol combination product patient diagnose open-angle glaucoma ocular hypertension . This global study conduct US ( C-07-64 , NCT00672997 ) Japan ( C-08-08 , NCT00760539 ) .</brief_summary>
	<brief_title>A Phase III Study Travoprost/Timolol Combination Patients With Open-Angle Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Openangle glaucoma confirm ocular hypertension . Mean IOP least one eye , eye ( ) :2236 mmHg 9 AM eligibility visit 1 &amp; 2 2136 mmHg 11 AM 4 PM Eligibility Visits 1 &amp; 2 . Sign inform consent form . Discontinued use IOPlowering medication ( ) minimum 4 day minimum 27 day prior Eligibility 1 Visit . Other protocoldefined inclusion criterion may apply . Females childbearing potential pregnant , plan become pregnant study period , breastfeeding , use adequate birth control measure . Any form glaucoma openangle glaucoma ( without pigment dispersion pseudoexfoliation component ) confirm ocular hypertension . History current evidence chronic recurrent severe inflammatory eye disease either eye . History current evidence clinically relevant progressive retinal disease retinal degeneration , diabetic retinopathy , retinal detachment either eye . Bestcorrected visual acuity ( BCVA ) worse 0.6 logMAR either eye . Severe central visual field loss either eye . Not able safely discontinue use IOPlowering ocular medication ( ) accord Ocular Hypotensive Medication Washout Schedule . History current evidence bronchial asthma , severe chronic obstructive pulmonary disease ( COPD ) would opinion investigator preclude safe administration topical betablocker . History evidence severe illness condition would make subject , opinion investigator , unsuitable study . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Glaucoma</keyword>
	<keyword>Hypertension</keyword>
</DOC>